AAPL   393.67 (+2.60%)
FB   248.20 (+1.28%)
GOOGL   1,549.40 (+0.68%)
NVDA   429.69 (+2.51%)
CGC   17.57 (+0.86%)
BABA   262.32 (+0.50%)
TSLA   1,718.48 (+11.25%)
AMD   57.68 (+3.22%)
GILD   76.83 (+0.67%)
DIS   118.75 (-0.49%)
NFLX   573.28 (+4.47%)
AAPL   393.67 (+2.60%)
FB   248.20 (+1.28%)
GOOGL   1,549.40 (+0.68%)
NVDA   429.69 (+2.51%)
CGC   17.57 (+0.86%)
BABA   262.32 (+0.50%)
TSLA   1,718.48 (+11.25%)
AMD   57.68 (+3.22%)
GILD   76.83 (+0.67%)
DIS   118.75 (-0.49%)
NFLX   573.28 (+4.47%)
AAPL   393.67 (+2.60%)
FB   248.20 (+1.28%)
GOOGL   1,549.40 (+0.68%)
NVDA   429.69 (+2.51%)
CGC   17.57 (+0.86%)
BABA   262.32 (+0.50%)
TSLA   1,718.48 (+11.25%)
AMD   57.68 (+3.22%)
GILD   76.83 (+0.67%)
DIS   118.75 (-0.49%)
NFLX   573.28 (+4.47%)
AAPL   393.67 (+2.60%)
FB   248.20 (+1.28%)
GOOGL   1,549.40 (+0.68%)
NVDA   429.69 (+2.51%)
CGC   17.57 (+0.86%)
BABA   262.32 (+0.50%)
TSLA   1,718.48 (+11.25%)
AMD   57.68 (+3.22%)
GILD   76.83 (+0.67%)
DIS   118.75 (-0.49%)
NFLX   573.28 (+4.47%)
Log in

OTCMKTS:GBLXGB Sciences Stock Price, Forecast & News

$0.03
0.00 (0.00 %)
(As of 07/13/2020 09:46 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.04
50-Day Range
$0.03
MA: $0.03
$0.04
52-Week Range
$0.02
Now: $0.03
$0.15
Volume151,800 shs
Average Volume362,903 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. The company is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. GB Sciences, Inc. has an agreement with Growblox Sciences, Puerto Rico, LLC that grants the right to its technology and intellectual property. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:GBLX
CUSIPN/A
Phone+1-888-8953594

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees60
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive GBLX News and Ratings via Email

Sign-up to receive the latest news and ratings for GBLX and its competitors with MarketBeat's FREE daily newsletter.

GB Sciences (OTCMKTS:GBLX) Frequently Asked Questions

How has GB Sciences' stock been impacted by COVID-19 (Coronavirus)?

GB Sciences' stock was trading at $0.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GBLX stock has increased by 0.0% and is now trading at $0.03. View which stocks have been most impacted by Coronavirus.

When is GB Sciences' next earnings date?

GB Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for GB Sciences.

How were GB Sciences' earnings last quarter?

GB Sciences Inc (OTCMKTS:GBLX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. View GB Sciences' earnings history.

Has GB Sciences been receiving favorable news coverage?

News coverage about GBLX stock has trended very negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GB Sciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about GB Sciences.

Who are some of GB Sciences' key competitors?

What other stocks do shareholders of GB Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), InMed Pharmaceuticals (IMLFF), KushCo (KSHB), mCig (MCIG), Medical Marijuana (MJNA), MassRoots (MSRT), Surna (SRNA), Marimed (MRMD) and PotNetwork (POTN).

Who are GB Sciences' key executives?

GB Sciences' management team includes the following people:
  • Mr. John C. Poss, Chairman & CEO (Age 71)
  • Ms. Ksenia Griswold, COO, CFO, VP & Controller (Age 36)
  • Dr. Andrea Small-Howard M.B.A., Ph.D., MBA, Chief Science Officer & Director (Age 50)
  • Mr. Krin Ellery Kuethe, Sr. VP of Cultivation (Age 35)
  • Mr. John B. Davis, Gen. Counsel & Exec. VP

What is GB Sciences' stock symbol?

GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."

How do I buy shares of GB Sciences?

Shares of GBLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GB Sciences' stock price today?

One share of GBLX stock can currently be purchased for approximately $0.03.

What is GB Sciences' official website?

The official website for GB Sciences is gbsciences.com.

How can I contact GB Sciences?

GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The company can be reached via phone at +1-888-8953594.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.